LEO Pharma Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$15.9M
Doctors Paid
18,321
Transactions
199,627
2024 Total
$3.3M
Payment Breakdown by Category
Consulting$5.1M (32.1%)
Food & Beverage$3.8M (23.7%)
Research$2.6M (16.4%)
Travel$516,037 (3.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $5.1M | 3,230 | 32.1% |
| Food and Beverage | $3.8M | 192,065 | 23.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3.3M | 1,183 | 20.6% |
| Unspecified | $2.6M | 71 | 16.4% |
| Travel and Lodging | $516,037 | 1,276 | 3.3% |
| Grant | $432,075 | 4 | 2.7% |
| Space rental or facility fees (teaching hospital only) | $165,667 | 56 | 1.0% |
| Education | $33,558 | 1,742 | 0.2% |
Payments by Type
General
$13.3M
199,556 transactions
Research
$2.6M
71 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| COND. APPROVED THE SAFETY & EFFICACY OF ENSTILAR SPRAY FOAM VS FOAM VEHICLE ON TARGET LESIONS TLSS IN PATIENTS WITH MODERATE PLAQUE PSORIASIS | $478,654 | 1 | 14 |
| A SINGLE-CENTER, OPEN-LABEL STUDY TO EVALUATE TRALOKINUMAB IN ATOPIC DEMATITIS SUBJECTS WHO EXPERIENCED INADEQUATE RESPONSE ON DUPILUMAB | $386,227 | 1 | 3 |
| THE SAFETY AND EFFICACY OF ADBRY IN SKIN OF COLOR PATIENTS WITH ATOPIC DERMATITIS IN THE REAL-WORLD SETTING | $381,994 | 1 | 6 |
| THE MAINTENANCE EFFECT OF ENSTILAR FOAM IN COMBINATION WITH OTEZLA | $197,758 | 1 | 4 |
| CONDITIONALLY APPROVED SAFETY AND EFFICACY OF INGENOL MEBUTATE GEL 0.015 FOR TREATMENT OF ACTINIC KERATOSIS ON THE FACE IN SOLID ORGAN TRANSPLANT RECIPIENTS. | $184,300 | 1 | 9 |
| PENDING AN OPEN-LABEL, SINGLE-CENTER STUDY TO EVALUATE THE TOLERABILITY AND EFFICACY OF ENSTILAR CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE FOAM IN THE TREATMENT OF CHRONIC PLAQUE PSORIASIS IN PATIENTS WITH SKIN OF COLOR FITZPATRICK SKIN PHOTOTYPES IV-VI. | $165,202 | 1 | 7 |
| OPEN LABEL, OBSERVATIONAL STUDY, EVALUATING ENSTILAR QD IN PSORIASIS PATIENTS BEING TREATED WITH BIOLOGIC AGENTS | $132,027 | 1 | 4 |
| OPEN LABEL, OBSERVATIONAL STUDY, EVALUATING ENSTILAR CALCIPOTRIENEBETAMETHASONE DIPROPIONATE FOAM, 0.0050.064 QD IN PSORIASIS PATIENTS BEING TREATED WITH ETANERCEPT OR ADALIMUMAB | $126,650 | 1 | 2 |
| CELLULAR AND NEUROPHYSIOLOGIC MECHANISMS OF ITCHY PSORIATIC SCALP IN HUMANS AND ASSESSING THE EFFECT ENSTILAR ON REDUCING NEURAL ITCH SENSITIZATION OF THE SCALP | $101,075 | 1 | 2 |
| OPEN LABEL, IIS STUDY ON THE EFFICACY & SAFETY OF A 24-WEEK COURSE OF ENSTILAR CALCIPOTRIENEBETAMETHASONE DIPROPIONATE FOAM, 0.0050.064 APPLIED TWICE DAILY IN PATIENTS WITH NAIL PSORIASIS | $86,100 | 1 | 1 |
| OPEN LABEL, OBSERVATIONAL STUDY, EVALUATING ENSTILAR (CALCIPOTRIENE/BETAMETHASONE DIPROPIONATE) FOAM, 0.005%/0.064% QD IN PSORIASIS PATIENTS BEING TREATED WITH ETANERCEPT OR ADALIMUMAB | $70,000 | 1 | 2 |
| CHARACTERIZATION OF UNMET NEED FOR TARGETED PRECISION MEDICATION IN ATOPIC DERMATITIS DUE TO INADEQUATE OR POOR RESPONSE TO DUPILUMAB | $45,000 | 1 | 2 |
| OPEN LABEL, IIS STUDY ON THE EFFICACY & SAFETY OF A 24-WEEK COURSE OF ENSTILAR (CALCIPOTRIENE/BETAMETHASONE DIPROPIONATE) FOAM, 0.005%/0.064%) APPLIED TWICE DAILY IN PATIENTS WITH NAIL PSORIASIS | $44,479 | 1 | 2 |
| AN OPEN LABEL PROOF OF CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF INGENOL MEBUTATE 0.05 GEL FOR THE TREATMENT OF VERRUCA VULGARIS | $44,070 | 1 | 3 |
| OPEN LABEL IIS STUDY ON THE EFFICACY & SAFETY OF A 24-WEEK COURSE OF ENSTILAR (CALCIPOTRIENE/BETAMETHASONE DIPROPIONATE) FOAM 0.005%/0.064%) APPLIED TWICE DAILY IN PATIENTS WITH NAIL PSORIASIS | $41,365 | 1 | 2 |
| PICATO FOR THE TREATMENT OF MOLLUSCUM CONTAGIOSUM IN IMMUNOCOMPROMISED PATIENTS | $37,292 | 1 | 5 |
| PENDING: AN OPEN-LABEL, SINGLE-CENTER STUDY TO EVALUATE THE TOLERABILITY AND EFFICACY OF ENSTILAR? (CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE) FOAM IN THE TREATMENT OF CHRONIC PLAQUE PSORIASIS IN PATIENTS WITH SKIN OF COLOR (FITZPATRICK SKIN PHOTOTYPES IV-VI). | $30,000 | 1 | 1 |
| A SINGLE-CENTER OPEN-LABEL STUDY TO EVALUATE TRALOKINUMAB IN ATOPIC DEMATITIS SUBJECTS WHO EXPERIENCED INADEQUATE RESPONSE ON DUPILUMAB | $26,873 | 1 | 1 |
| THE IMPACT OF ENSTILAR ON THE COST OF A BIOLOGIC SWITCH | $25,000 | 1 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Leon Kircik, Md, MD | Dermatology | Lousiville, KY | $1.3M | $0 |
| Mr. Jerry Bagel, Md, MD | Dermatology | East Windsor, NJ | $767,524 | $0 |
| Firas Hougeir, M.d, M.D | MOHS-Micrographic Surgery | Douglasville, GA | $337,478 | $0 |
| Adrian Rodriguez, Md, MD | Dermatology | Nashville, TN | $272,432 | $0 |
| Andrew Alexis, Md, MD | Dermatology | New York, NY | $250,163 | $0 |
| Dr. Matthew Zirwas, Md, MD | Dermatology | Bexley, OH | $240,113 | $0 |
| Boni Elewski | Dermatology | Birmingham, AL | $199,545 | $0 |
| Dr. Jonathan Silverberg, Md, Phd, Mph, MD, PHD, MPH | Dermatology | Washington, DC | $190,432 | $0 |
| Linda Stein Gold, M.d, M.D | Dermatology | West Bloomfield, MI | $185,780 | $0 |
| Sarah Arron, M.d., Ph.d, M.D., PH.D | Procedural Dermatology | Burlingame, CA | $184,418 | $0 |
| Neal Bhatia, Md, MD | Dermatology | San Diego, CA | $172,866 | $0 |
| Dr. Naiem Issa, M.d., Ph.d, M.D., PH.D | Dermatology | Vienna, VA | $163,418 | $0 |
| Dr. James Del Rosso, Do, DO | MOHS-Micrographic Surgery | Las Vegas, NV | $162,223 | $0 |
| Mr. Michael Cameron | Dermatology | New York, NY | $141,747 | $0 |
| Dr. Paul Yamauchi, M.d., Phd, M.D., PHD | Dermatology | Santa Monica, CA | $125,307 | $0 |
| Dr. John Koo, Md, MD | Dermatology | San Francisco, CA | $123,379 | $0 |
| Gil Yosipovitch, Md, MD | Dermatology | Miami, FL | $123,107 | $0 |
| Dr. Cory Rubin, M.d, M.D | Clinical & Laboratory Dermatological Immunology | Waterford, MI | $118,473 | $0 |
| John Kasteler, M.d, M.D | Dermatology | Gilbert, AZ | $115,460 | $0 |
| David Cohen, M.d, M.D | Dermatology | New York, NY | $111,731 | $0 |
| Benjamin Ehst, M.d., Ph.d, M.D., PH.D | Dermatology | Portland, OR | $109,132 | $0 |
| Mona Shahriari | Dermatology | Cromwell, CT | $109,028 | $0 |
| Scott Guenthner, Md, MD | Dermatology | Plainfield, IN | $107,242 | $0 |
| Dr. Christopher Bunick, M.d., Ph.d, M.D., PH.D | Student in an Organized Health Care Education/Training Program | New Haven, CT | $104,746 | $0 |
| April Armstrong, Md, MD | Clinical & Laboratory Dermatological Immunology | Los Angeles, CA | $103,638 | $0 |
About LEO Pharma Inc.
LEO Pharma Inc. has made $15.9M in payments to 18,321 healthcare providers, recorded across 199,627 transactions in the CMS Open Payments database. In 2024, the company paid $3.3M. The top product by payment volume is ADBRY ($8.7M).
Payments were distributed across 158 medical specialties. The top specialty by payment amount is Dermatology ($10.0M to 6,745 doctors).
Payment categories include: Food & Beverage ($3.8M), Consulting ($5.1M), Research ($2.6M), Travel & Lodging ($516,037).
LEO Pharma Inc. is associated with 4 products in the CMS Open Payments database, including ADBRY, ENSTILAR, and PICATO.